Amylyx Pharmaceuticals, Inc.
AMLX
$14.44
-$0.44-2.96%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 24.82% | -7.33% | -9.94% | -11.53% | -85.54% |
| Gross Profit | -24.82% | 9.95% | 8.21% | 14.38% | 65.64% |
| SG&A Expenses | 3.09% | -9.97% | -9.29% | -27.75% | -72.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.81% | -8.46% | -9.65% | -18.23% | -82.06% |
| Operating Income | -15.81% | 9.96% | 8.70% | 19.80% | 69.05% |
| Income Before Tax | -14.97% | 13.69% | 52.70% | 42.99% | 69.71% |
| Income Tax Expenses | -- | 107.24% | -- | -- | -- |
| Earnings from Continuing Operations | -14.97% | 12.11% | 52.70% | 42.99% | 69.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.97% | 12.11% | 52.70% | 42.99% | 69.77% |
| EBIT | -15.81% | 9.96% | 8.70% | 19.80% | 69.05% |
| EBITDA | -16.03% | 9.87% | 8.49% | 19.75% | 69.09% |
| EPS Basic | 10.88% | 45.12% | 65.50% | 56.50% | 76.07% |
| Normalized Basic EPS | 10.88% | 49.99% | 31.25% | 36.55% | 76.02% |
| EPS Diluted | 10.88% | 45.12% | 65.50% | 56.50% | 76.07% |
| Normalized Diluted EPS | 10.88% | 49.99% | 31.25% | 36.55% | 76.02% |
| Average Basic Shares Outstanding | 29.02% | 60.13% | 37.07% | 31.04% | 26.30% |
| Average Diluted Shares Outstanding | 29.02% | 60.13% | 37.07% | 31.04% | 26.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |